A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer
← catalyst calendarNCT06735742 · readout in 954 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
3actual
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-12 | actual | When the study began enrolling |
| Primary completion | 2029-03-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer
Primary outcome
what the primary-completion date above is the date OFIncidence of adverse drug reactions
measured Up to 52 weeks
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed